Amplia has today announced that it has completed the planned enrolment of the ACCENT Phase 2a clinical trial.
The two-stage ACCENT trial is investigating the use of the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapy in first-line patients with advanced pancreatic cancer.
Since opening recruitment in January 2024, the trial has enrolled 53 patients, which means full recruitment has been achieved two months ahead of schedule
Amplia CEO and MD Dr Chris Burns commented:
“To complete recruitment of the ACCENT trial well ahead of schedule is a direct result of the focused and diligent effort of the Amplia team and our clinical partners. Safety and efficacy data for the patients on study continues to be collected and trial updates will be reported in due course. We now anticipate top-line data from the study to be available mid-Q3 2025. As always, we thank the patients and their loved ones for their involvement with the trial.”
Click to read the ASX release.
